Drug discovery companies identify, validate and develop new therapeutic candidates for the prevention and treatment of disease. The sector combines biology, chemistry, data science and clinical expertise to bring new medicines from concept to clinic.
This category includes companies working on:
Browse 422 UK drug discovery companies below.
Human skin explant CRO for immunotoxicity and drug safety testing
Alcyomics is a contract research organisation providing non-animal, human-based in vitro safety and efficacy testing services to pharmaceutical, biotechnology, and cosmetics…
AstraZeneca's rare disease arm targeting the complement cascade
Alexion, AstraZeneca Rare Disease is the rare disease group within AstraZeneca, formed following the 2021 acquisition of Alexion Pharmaceuticals. With nearly 30 years of rare…
Antibody therapies depleting pathogenic T cells for autoimmune disease cure
Re-Aim Therapeutics is a biotechnology company developing antibody-based therapies designed to achieve functional cures for T cell-mediated autoimmune diseases. The company's…
Antibody therapy to deplete amyloid deposits in ATTR cardiomyopathy
Immutrin is a biotechnology company developing an engineered antibody therapeutic designed to actively remove amyloid deposits from tissues in patients with amyloidosis. Its lead…
Synthetic plant metabolites for osteoarthritis and age-related disease
AKL Therapeutics is a privately held UK pharmaceutical company developing APPA, a patented oral investigational medicine combining two synthetic plant metabolites that act…
In vivo cell reprogramming therapies for degenerative disease
Mogrify is a biotechnology company developing a novel class of in vivo reprogramming therapies for degenerative diseases. Its proprietary platforms use large-scale transcriptomic…
Autophagy-enhancing small molecule drugs for neurodegeneration and rare disease
Samsara Therapeutics is a drug discovery company developing first-in-class small molecule therapeutics that restore autophagy, the cellular process of degrading and recycling…
Next-generation targeted protein degradation therapeutics
Amphista Therapeutics is a Cambridge-based biopharmaceutical company developing next-generation targeted protein degradation medicines. Its proprietary platform generates…
Clinical-stage peptide therapeutics for autoimmune and infectious disease
ImmuPharma is a clinical-stage biopharmaceutical company developing peptide-based therapeutics and precision diagnostics for autoimmune disease, infectious disease and metabolic…
Hypoxia-activated CAR-T cell therapy platform for solid tumour cancers
Korecyte Bio is a preclinical-stage cell therapy company developing HypoxiCAR, a modular CAR-T platform for treating solid tumours. The technology uses a dual-sensor genetic…
Cyclic peptide screening platform for first-in-class cancer drugs
Curve Therapeutics is a drug discovery company using its proprietary platform to identify first-in-class small molecule therapeutics against targets that have been difficult to…
Preclinical immunology CRO for drug discovery programmes
Nexus BioQuest is a contract research organisation specialising in preclinical immunology services for the biotechnology and pharmaceutical industries. The company offers bespoke…